Alto Neuroscience (stock code: ANRO) has successfully completed patient enrollment for its Phase II proof-of-concept study of the candidate drug Alto-101 for cognitive impairment associated with schizophrenia.
Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
The completion of this study marks an important milestone in the clinical development process of the drug, laying a foundation for subsequent evaluation of its efficacy and safety.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now！
You may also like
Star: Rumors of an exchange hack are false
AiCoin•2026/10/31 05:45
Ozzy: StepDrainer attack expands to multiple DeFi projects
AiCoin•2026/10/31 03:47
The annualized deposit yield is 9.58%, Pendle launches its second ecosystem vault on Morpho.
Odaily星球日报•2026/10/31 01:47
France's fiscal outlook deteriorates as Fitch revises rating outlook to negative
Due to the deterioration of public finances, including slower growth, rising borrowing costs, and widening deficits, Fitch Ratings has revised France's credit rating outlook to negative.
智通财经•2026/10/31 01:46
Crypto prices
More
Bitcoin
BTC
$77,129.83
-1.63%
Ethereum
ETH
$2,238.56
-0.01%
Tether USDt
USDT
$0.9989
+0.09%
BNB
BNB
$701.99
-2.04%
XRP
XRP
$1.25
-0.98%
USDC
USDC
$0.9997
+0.02%
Solana
SOL
$95.83
-2.09%
TRON
TRX
$0.3240
-3.73%
Hyperliquid
HYPE
$88.32
-4.50%
Zcash
ZEC
$1,258.29
-0.88%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now